

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_80393
Title of the Manuscript:	Oral manifestations of COVID-19 in adult patients: Systematic Review.
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	<p>Review of the article entitled Oral manifestations of COVID-19 in adult patients: Systematic Review., MS JPRI 80393</p> <p>This review article is within the scope of the journal, well written and maintains conceptual and methodological coherence. Appropriate data and sources were used in order to identify the oral manifestations of COVID-19 in adult patients and adequate references were properly cited. It is suitable for publication after some revision.</p> <p>The English language should be improved at some places. On page 1, in the abstract, line 2, add comma before, such as In the introduction, paragraph 2, lines 1 and 2, state It is a virus, instead of It a virus On page 2, paragraph 1, line 2, use singular for generalized myalgia, instead of myalgias Line 4, micro biota can be divided, as well as in the rest of the manuscript Present Table 1 after its mentioning in the last sentence on this page</p> <p>On page 4, present Figure 1, Figure 2 and Table 2 after their mentioning in the second paragraph. Paragraph 3, line 4, correct spelling multiform, instead of multiforme Paragraph 4, lines 3 and 4, state, since for some patients taking of ibuprofen can cause the inhibition of platelet function Paragraph 5, line 4, micro bacteria can be divided</p> <p>On page 5, paragraph 3, line 2, use comma before, such as Paragraph 5, lines 7 and 10, use superscript for reference 53, and add one space after it infection,⁵³ showing herpes,⁵³ and Line 15, micro biota can be divided</p> <p>On page 6, paragraph 3, line 1, micro biome can be divided Paragraph 5, line 4, use comma before, such as Paragraph 6, line 2, state 0.12 % chlorhexidine, instead of 12%</p> <p>On page 7, paragraph 1, line 3, micro biota can be divided Paragraph 3, line 3, use comma before, since it Paragraph 5, line 6, state immune compromised patients, instead of</p>	

Review Form 1.6

	<p>immunocompromised On page 8, in conclusion, paragraph 1, line 5, correct spelling patients Line 3, use singular for antihypertensive Line 12, state herpetic form, instead of herpetiform Paragraph 2, line 6, sub gingival can be divided</p> <p>Add the number of the last page to references 4, 14, 17, 27, 34, 48, 49, 50, 56, 66, 68, 69, 80, 81, 83, 85, 90, 91, 93, 94, 97 and 99 Provide page numbers in references 5, 46 and 77 Provide issue numbers in references 38, 42, 69, 71, 73, 74, 85, 90 Provide volume and issue numbers in references 70, 76 and 101 Provide volume, issue and pages in references 16, 22, 23, 24, 56, 62, 67, 82, 87, 88, 95 and 96, if available Add year to reference 10, before volume and issue number Format the entire manuscript according to the style of the journal.</p> <p>In Figure 1, correct 36 % for Europe, like in the text of the manuscript, instead of 35 % In Figure 2, correct spelling, number of excluded articles, instead of articles</p>	
<p><u>Optional/General</u> comments</p>	<p>This review article is within the scope of the journal, well written and maintains conceptual and methodological coherence. Appropriate data and sources were used in order to identify the oral manifestations of COVID-19 in adult patients and adequate references were properly cited. It is suitable for publication after some revision.</p>	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Are there ethical issues in this manuscript?</p>	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i> There are no ethical issues in this manuscript</p>	
<p>Are there competing interest issues in this manuscript?</p>	<p>There are no competing interest issues in this manuscript</p>	
<p>If plagiarism is suspected, please provide related proofs or web links.</p>	<p>There is no plagiarism suspected in this manuscript</p>	

Review Form 1.6

PART 3: Declaration of Competing Interest of the reviewer:

Here reviewer should declare his/her competing interest. If nothing to declare he/she can write "I declare that I have no competing interest as a reviewer"

I declare that I have no competing interest as a reviewer

PART 4: Objective Evaluation:

Guideline	MARKS of this manuscript
Give OVERALL MARKS you want to give to this manuscript (Highest: 10 Lowest: 0) Guideline: Accept As It Is: (>9-10) Minor Revision: (>8-9) Major Revision: (>7-8) Serious Major revision: (>5-7) Rejected (with repairable deficiencies and may be reconsidered): (>3-5) Strongly rejected (with irreparable deficiencies.): (>0-3)	Minor Revision: (>8-9)

PART 5: Reviewer Details:

This information is mandatory to prepare the Reviewer Certificate properly.
Certificate preparation will not be possible if incomplete information is received.

Name of the Reviewer	Tamara Jovanovic
Department of Reviewer	Department of Biomedical Engineering
University or Institution of Reviewer	Faculty of Mechanical Engineering, University of Belgrade
Country of Reviewer	Serbia
Position: (Professor/lecturer, etc.) of Reviewer	Dr, Associate Research Professor
Email ID of Reviewer	tamara.jovanovic@sbb.rs tjovanovic@mas.bg.ac.rs
WhatsApp Number of Reviewer	Tel: +381 11 3541 885
5-8 Keywords regarding expertise of Reviewer	Materials, chemistry, medicinal and pharmaceutical chemistry, chemical technologies, nanotechnologies, biomedical engineering, spectroscopy